by Shannon Tomlinson | Sep 5, 2025 | News
Abselion’s CEO, Dr. Ruizhi Wang, was recently featured in a BioCompare editorial article, “Cell-Based Gene Therapies: Challenges and Advances in Upstream Manufacturing.” The piece brings together perspectives from leaders across the field, highlighting the hurdles and...
by abselionGF | Aug 28, 2025 | News
Abselion is featured in Biocompare’s latest editorial on antibody libraries — indispensable tools for research and drug discovery. In this Q&A, Dr. Ruizhi Wang discusses how antibody libraries are shaping the future of therapeutic development, from enabling novel...
by Shi-qi An | Apr 24, 2025 | News
NHS Blood and Transplant Clinical Biotechnology Centre implements the Amperia™ system to streamline viral vector process development for novel gene therapies The NHSBT Clinical Biotechnology Centre (CBC), Bristol, one of three government selected Innovation Hubs...
by Shi-qi An | Apr 9, 2025 | News
We’re excited to share that Abselion is featured in the Spring 2025 issue of Innovations in Pharmaceutical Technology (IPT), highlighting the role of our Amperia system in advancing at-line protein quantification for biologics and viral vector development. The article...
by Shi-qi An | Mar 4, 2025 | News
Abselion is delighted to announce the appointment of Kim Orton-Smith as Vice President of Sales & Marketing. Kim brings 19 years of global commercial experience in life sciences, with a track record of turning product innovation into scalable revenues and driving...
by Shi-qi An | Jan 2, 2025 | News
A warm welcome to our new board members, Dr Oliver Hardick of M Ventures and Chris Major of BioProcess 360 Partners. Oliver is Entrepreneur in Residence in the Biotechnology team at M Ventures, with a focus on life science tools & technology innovation. Having...
